Navigation Links
Diamyd(R) Phase III Study Approved for Younger Patients in the US

STOCKHOLM, June 8 /PRNewswire-FirstCall/ -- Diamyd Medical reported today that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company's Phase III study with the diabetes vaccine Diamyd(R).

(Logo: )

Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients. The objective of the studies is to evaluate the ability of the Diamyd(R) vaccine to halt or delay the autoimmune attack on the body's insulin-producing cells, thereby preserving the body's own ability to produce insulin in children and adolescents with recent-onset type 1 diabetes.

The European study, which is being conducted in nine countries, is approved for patients between 10 and 20 years of age, whilst the US study so far has been approved only for patients 16 to 20 years, an age group with few recent-onset type 1 diabetes patients. The company is, with the new approval, allowed to begin enrollment of children from 10 years of age in the US phase III study.

"This is a big step forward giving us the opportunity to accelerate patient recruitment in the US," says Elisabeth Lindner, President and CEO of Diamyd Medical. "We are pleased that the approval comes now in connection with the world's largest diabetes conference, the ADA's 69th Scientific Sessions, which is currently ongoing in New Orleans."

The company will now, in pace with Institutional Review Board (IRB) approvals in USA, increase the number of American pediatric clinics in the study. The application for market approval is, as before, planned for spring 2011.

Diamyd Medical is represented at booth #2431 at the ADA's 69th Scientific Sessions in New Orleans, USA.

About Diamyd Medical

Diamyd Medical is a Swedish biopharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd(R) for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has started clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease. The company has currently three clinical-phase products.

Diamyd Medical has offices in Sweden and in the US. Shares are listed on the Nasdaq OMX Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company's website:

This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements. <start table>

    For additional information, please contact:
    Elisabeth Lindner,
    President and CEO Diamyd Medical AB (publ.),
    Tel: +46(0)8-661-00-26.

    For pictures and press material, please contact:
    Alexandra Fleetwood,
    Director Communications Diamyd Medical AB (publ.),,
    Tel: +46(0)8-661-00-26. <end table>

SOURCE Diamyd Medical AB (publ)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
4. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
5. Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
8. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
9. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
10. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
11. Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Post Your Comments:
(Date:10/8/2015)... MADISON, N.J. , Oct. 8, 2015  Genetic ... guidelines may aid the identification of more couples at ... to a study presented today at the 2015 American ... through October 10 in Baltimore, Maryland ... from Quest Diagnostics (NYSE: DGX ) are presenting ...
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... , ... October 08, 2015 , ... Talon Innovations, a ... Aerospace and other technology-driven industries, announces that it is one of three finalists for ... Midsize Company.” On Thursday, September 25 Talon Innovations was recognized as a nominee ...
Breaking Biology Technology:
... Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today reported a summary of recent ... and nine months ended September 30, 2011. ... the first nine months of this year," said James ...
... Nov. 10, 2011 Theravalues, a Japan ... impacts positively on the prevention of heart failure and ... the human clinical trial started with the registration in ... Organization Kyoto Medical Center and University of Shizuoka, Japan, ...
... Kluwer Pharma Solutions, a leading provider of scientific information ... to investors through Bloomberg Tradebook,s Independent Research Provider (IRP) ... in Thought™, Wolters Kluwer Pharma Solutions, research ... pharmaceutical drugs and medical devices. ...
Cached Biology Technology:
(Date:9/10/2015)... Report Details The global wearable ... previous expectations of revenues, consumer adoption and even technological ... which wearables begin to achieve that mass market acceptance ... reasons is the entrance of Apple to the SmartWatches ... but the overall size of the wearable technology market. ...
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security ... and solution-based milestones, furthering the company,s commitment to ... online fraud. NuData Security,s online fraud ... the company,s growth cycle. The product combines continual ... determine good user behavior from fraudulent behavior, allowing ...
(Date:9/2/2015)... Sept. 2, 2015 About hand geometry biometrics ... banks, government organizations, telecommunication and hospitals as well as ... badges, and numeric keypads are used to prevent unauthorised ... palm and fingers of an individual, width of the ... with infrared light and reflectors can be used for ...
Breaking Biology News(10 mins):
... School of Medicine (BUSM) have found a link ... HIV-infected persons. The study appears online in the ... Deficiency Syndromes., Alcohol use is common among HIV-infected ... has been examined in in-vitro, animal and human ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... The sensor components resemble a pregnancy test ...
... biological systems engineering, is leading the team of ... Sciences ( ) at Virginia Tech ( ... convert poultry litter into bio-oil, providing an economical ... issues. Agblevor will present the research during ...
Cached Biology News:
... The high-performance triple quadrupole 1200L sets ... today's cost-conscious environment - incorporating the ... for all liquid chromatography analytical needs. ... interface and the Transmission Quadrupole Analyzer ...
C1-inhibitor (C1-INH)...
... ATP-Free using Mo Bio luciferase assay. Mo Bio ... that will allow you to certify your products ... enable you to deliver them to your customers ... detection limit is 3.5 x 10-12 /l, which ...
Choriongonadotropin (human, hCG)...
Biology Products: